Table 4.
Univariate analysis for overall survival and progression-free survival
| Outcomes | P value | Hazard ratio |
|---|---|---|
| Overall survival | ||
| Age >65 y | .0114 | 1.729 |
| KPS >80 | .0008 | 0.425 |
| Weight loss >30 lbs | .4496 | 0.832 |
| Hgb >12 g/dL | .5618 | 0.887 |
| CA19-9 >1000 U/mL | .2552 | 1.378 |
| Tumor size >3 cm | .8786 | 1.040 |
| Pancreatic head involvement | .6266 | 1.107 |
| Induction chemotherapy | .3439 | 0.573 |
| 5-FU vs gemcitabine (concurrent chemotherapy) | .1904 | 0.705 |
| Treatment break | .0006 | 2.073 |
| Toxicity break vs no break | .0021 | 1.955 |
| Planned break vs no break | .2848 | 1.654 |
| Palliative procedure | .1275 | |
| Bypass vs none | .1481 | 0.667 |
| Stent vs none | .6371 | 1.121 |
| Stent vs bypass | .0400 | 1.680 |
| Local disease status at 1st post-therapy imaging | .0261 | |
| Partial response vs progressive disease | .0266 | 0.364 |
| Stable disease vs progressive disease | .0089 | 0.415 |
| Partial response vs stable disease | .7058 | 0.877 |
| Best local response | .0223 | |
| Partial response vs progressive disease | .0099 | 0.346 |
| Stable disease vs progressive disease | .0115 | 0.425 |
| Partial response vs stable disease | .4803 | 0.814 |
| Progression-free survival | ||
| Age >65 y | .0662 | 1.474 |
| KPS >80 | .0056 | 0.507 |
| Weight loss >30 lbs | .6661 | 1.107 |
| Hgb >12 g/dL | .7331 | 2.115 |
| CA19-9 >1000 U/mL | .0084 | 2.115 |
| Tumor size >3 cm | .3655 | 1.251 |
| Pancreatic head involvement | .8779 | 1.031 |
| Induction chemotherapy | .2107 | 0.527 |
| 5-FU vs gemcitabine (concurrent chemotherapy) | .6406 | 0.887 |
| Treatment break | .0020 | 1.910 |
| Toxicity break vs no break | .0140 | 1.680 |
| Planned break vs no break | .0908 | 2.245 |
| Palliative procedure | .3397 | |
| Bypass vs nothing | .1463 | 0.683 |
| Stent vs nothing | .5790 | 0.878 |
| Bypass vs stent | .3080 | 0.778 |
KPS, Karnofsky performance status; Hgb, hemoglobin.